Android Apple

Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment

By MarketWatch   |   2 months ago
Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment

Aldeyra Therapeutics has resubmitted its proposed reproxalap drug to the FDA for treating dry-eye disease, including new trial results. The resubmission also includes data on reducing dry-eye symptoms and ocular redness.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.